Clinical trial Recruiting at 1 site Early Phase 1 Interventional Ages 25 to 50

Montelukast for protecting cartilage after ACL surgery

Official title: MOntelukast as a Potential CHondroprotective Treatment Following Anterior Cruciate Ligament Reconstruction (MOCHA Trial)

Run by University of Kentucky · NCT04572256 · Data updated 2026-11-12

This study is testing if taking montelukast for six months after ACL surgery can help older patients reduce inflammation and protect their cartilage from damage.

Quick facts

PhaseEarly Phase 1
Study typeInterventional
Ages25 Years to 50 Years
SexAll
Enrollment30 (estimated)
SponsorUniversity of Kentucky
Academic / other
Locations1 site (Lexington, Kentucky)
StatusRecruiting
StartedFebruary 1, 2021
Main results expectedJune 2027
Study endsJune 2027
Registry record updatedJune 10, 2026
Trial IDNCT04572256 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are individuals aged 25-50 who are undergoing primary ACL reconstruction with a concomitant meniscus injury.

Probably not a fit

Patients undergoing revision procedures or those without a meniscus tear at the time of surgery may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter randomized, placebo-controlled trial investigates the effects of a 6-month course of oral montelukast on reducing inflammation and cartilage degradation following anterior cruciate ligament (ACL) reconstruction. Targeting older patients with ACL and meniscus injuries, the study aims to determine if montelukast can mitigate the risk of post-traumatic osteoarthritis (PTOA) progression. Participants will be randomly assigned to receive either montelukast or a placebo daily for six months after their surgery, with assessments of systemic inflammation and cartilage biomarkers conducted throughout the study.

Why it matters

Potential benefit: If successful, this treatment could significantly reduce the risk of developing post-traumatic osteoarthritis in patients undergoing ACL reconstruction.

How similar studies have gone: While the approach of using montelukast for cartilage protection is novel, previous studies have shown promise in using anti-inflammatory treatments to reduce cartilage degradation post-injury.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Undergoing primary ACL reconstruction
2. Age between 25-50
3. Concomitant meniscus injury

Exclusion Criteria:

1. Undergoing revision procedures
2. Multiple ligament injuries requiring multiple ligament reconstruction/repair
3. Depressive symptoms and/or those who endorse suicidal ideation at the time of enrollment (PHQ-9 score \>= 15)
4. Found to not have a meniscus tear at the time of surgery

Where it's running

  • UK Healthcare at Turfland
    Lexington, Kentucky, United States
    Recruiting

Study contacts

  • Principal investigator: Austin Stone, MD, PhD — University of Kentucky
  • Study coordinator: Austin Stone, MD, PhD
  • Email: austin.stone@uky.edu
  • Phone: 859.218.3065

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.